Nirsevimab and Abrysvo Availability for the 2025-2026 Respiratory Season

Nirsevimab Availability Through the VFC Program

Preparations have begun for the upcoming respiratory syncytial virus (RSV) season (September through March). The Ohio Department of Health (ODH) VFC program plans to make nirsevimab available for ordering through the ImpactSIIS Vaccine Ordering Management System (VOMS) beginning in August 2025. At that time, VFC providers will be able to find nirsevimab in the VFC RSV order set.

Similar to last year, Ohio will receive biweekly nirsevimab thresholds of both 50mg and 100mg presentations from the Centers for Disease Control and Prevention (CDC). If an allocation is exhausted, the product will be restricted from ordering until the next biweekly replenishment. An ImpactSIIS message of the day will be added to notify VFC providers of any nirsevimab ordering restrictions.

Nirsevimab administration should start in October. Ordering products now allows sufficient time for all of Ohio’s VFC providers to obtain adequate stock of products when considering the biweekly thresholds.

VFC Nirsevimab Ordering Caps

There will be a per-order cap for all Ohio VFC providers of 100 doses for each presentation. Providers should use their VFC provider profile data, current inventory, and historical administration of nirsevimab to help determine appropriate order quantities. A vaccine order may be reduced if there is a large discrepancy between an order amount and a provider’s profile data.

Orders will be processed on a first-come, first-served basis.

Nirsevimab Administration

Providers should administer nirsevimab to the following patients, starting Oct. 1, 2025:

  • All infants less than 8 months of age entering their first RSV season born to mothers who did not receive a maternal RSV vaccine (Pfizer’s Abrysvo) during pregnancy.
    • Infants born shortly before or during the RSV season (typically starting October 1 through March 31 in most of the continental U.S.) should receive nirsevimab within one week of birth. Nirsevimab administration can occur during the birth hospitalization or in an outpatient setting.
    • Only a single dose of nirsevimab is recommended for the infant’s first RSV season.
  • Young children age 8 to 19 months1 who remain vulnerable to severe RSV disease when entering their second RSV season.

Nirsevimab Product Information:

  • Beyfortus 50mg
    • VOMS Order Set:  VFC RSV.
    • Weight Indication: Under 5 kg (under 11 lbs.).
    • Presentation: Prefilled syringe; 5 pack.
    • Minimum Order Quantity: 5 doses.
  • Beyfortus 100mg
    • VOMS Order Set:  VFC RSV.
    • Weight Indication: 5+ kg (11+lbs.) and over.
    • Presentation: Prefilled syringe; 5 pack.
    • Minimum Order Quantity: 5 doses.

 

VFC Provider Planning Considerations for Nirsevimab

  • Ohio’s existing network of VFC providers serve as the main access point to nirsevimab for VFC eligible patients2.
  • Providers who have existing inventory of VFC nirsevimab remaining from the 2024-2025 respiratory season should not place orders for additional products until their inventory is low or nearly depleted.
  • Redistribution of nirsevimab to other VFC enrolled providers is not allowed. Each enrolled provider should place a VFC order only for their eligible patients.
  • While it is recommended to order nirsevimab early following initial availability, VFC providers will have the opportunity to order nirsevimab throughout the respiratory season.
  • VFC providers are advised to ensure there is adequate vaccine storage space in their refrigerators before placing vaccine orders.
  • The ODH vaccine ordering system VOMS is available for providers to place orders 24 hours a day, seven days a week.

 

Abrysvo Availability Through the VFC Program:

Abrysvo for VFC-eligible pregnant women will be available beginning in August through the VFC Program.  Abrysvo ordered through the VFC Program is to be administered to appropriate individuals who meet the ACIP recommendation eligibility and VFC eligibility criteria2

Abrysvo Product Information:

  • Abrysvo
    • VOMS Order Set: VFC-Abrysvo.
    • Indication: Pregnant women.
    • Presentation: Single dose vials.
    • Minimum Order Quantity: 1 dose.

Abrysvo Administration to Pregnant Women

Abrysvo vaccine, made by Pfizer, Inc., is the only RSV vaccine authorized for use during pregnancy; specifically, during gestational weeks 32 and zero days through 36 weeks and six days.

Do NOT administer Abrysvo to infants. The receipt of this vaccine is an option for pregnant women instead of having their infant receive an injection with a monoclonal antibody product during their first week of life for RSV prevention. Abrysvo can help reduce the severity of RSV illness for infants born during the active RSV season.

To be eligible for one dose of the VFC Abrysvo vaccine, a pregnant woman must meet all of the following criteria:

  • Time of year: Sept. 1 through Jan. 31 in Ohio.
  • Gestational age: between 32 weeks and 0 days through 36 weeks and 6 days of gestation.
  • Vaccination history: no history of a previous dose of any RSV vaccine.
  • Maternal preference: either maternal Abrysvo vaccination or nirsevimab preventive antibody administration to the infant is recommended. Infants do not generally need both forms of protection.
  • Meets VFC eligibility criteria2.
  • Abrysvo can be given at the same visit or at any time before or after other recommended vaccines (e.g., Tdap, influenza, or COVID-19 vaccine), using different anatomic sites.

 

Thank you for your partnership and efforts to prevent serious illness, hospitalization, and death from vaccine preventable diseases.

For questions about this information or the VFC Program, please call the ODH Immunization Program at 1-800-282-0546.

 

  1. Nirsevimab: 8- to-19-month old Eligibility Criteria:
  • Young children with chronic lung disease (CLD) of prematurity who required medical support during the six months (diuretics, oxygen, chronic steroids) before the start of the second RSV season.
  • Young children who are severely immunocompromised.
  • Young children with cystic fibrosis who have either:
    • manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable).
    • weight-for-length that is less than 10th percentile. 
  • American Indian and Alaska Native children (note that this is a new group for whom second-season prophylaxis is recommended in contrast to the current palivizumab recommendations). 

 

  1. VFC Vaccine Eligibility:

A child through 18 years of age is eligible to receive VFC vaccine if the child meets at least one of the following criteria:

  • Child is Medicaid eligible.
  • Child is uninsured.
  • Child is American Indian or Alaska Native.
  • Child is Underinsured: An underinsured child is eligible to receive VFC vaccine only through a federally qualified health center (FQHC), rural health clinic (RHC), or a public health department that receives deputized authority from a FQHC or RHC.

Underinsured includes a child who has health insurance but the policy:

  • Does not cover any ACIP-recommended vaccines. (Underinsured for all vaccines).
  • Does not cover certain ACIP-recommended vaccines. (Underinsured for non-covered vaccines only).
  • NEW: Does not provide first dollar coverage (which includes co-pays, co-insurance, or deductibles) for ACIP-recommended vaccines. (Underinsured for vaccines until the child has health insurance with first-dollar coverage for vaccines.)
  • Covers ACIP-recommended vaccines but has a fixed dollar limit (or cap) for payment. (Underinsured once the policy reaches the fixed dollar cap).